Extracellular vesicles as nature's nano carriers in cancer therapy: insights toward preclinical studies and clinical applications DOI Creative Commons
Xiaotong Wu,

Yuhua Meng,

Zhimeng Yao

et al.

Pharmacological Research, Journal Year: 2025, Volume and Issue: unknown, P. 107751 - 107751

Published: May 1, 2025

Extracellular vesicles (EVs), which are secreted by various cell types, hold significant potential for cancer therapy. However, there several challenges and difficulties that limit their application in clinical settings. This review, integrates the work of our team recent advancements this research field, discusses EV-based treatment strategies to guide application. The following discussed: 1) leveraging inherent properties EVs development treatments; 2) modifying using EV engineering methods improve drug loading delivery; 3) targeting key molecules tumor-derived (TDE) synthesis inhibit production; 4) clearing TDEs from tumor microenvironment. Additionally, on basis into vaccines bispecific antibodies, review elaborates enhance antitumor immunity via modifications can ability stability progress AI technology targeted delivery drugs. Although limited enhancing abilities, provides an in-depth discussion prior studies. Finally, summarizes use therapy highlights need be addressed.

Language: Английский

Extracellular vesicles as nature's nano carriers in cancer therapy: insights toward preclinical studies and clinical applications DOI Creative Commons
Xiaotong Wu,

Yuhua Meng,

Zhimeng Yao

et al.

Pharmacological Research, Journal Year: 2025, Volume and Issue: unknown, P. 107751 - 107751

Published: May 1, 2025

Extracellular vesicles (EVs), which are secreted by various cell types, hold significant potential for cancer therapy. However, there several challenges and difficulties that limit their application in clinical settings. This review, integrates the work of our team recent advancements this research field, discusses EV-based treatment strategies to guide application. The following discussed: 1) leveraging inherent properties EVs development treatments; 2) modifying using EV engineering methods improve drug loading delivery; 3) targeting key molecules tumor-derived (TDE) synthesis inhibit production; 4) clearing TDEs from tumor microenvironment. Additionally, on basis into vaccines bispecific antibodies, review elaborates enhance antitumor immunity via modifications can ability stability progress AI technology targeted delivery drugs. Although limited enhancing abilities, provides an in-depth discussion prior studies. Finally, summarizes use therapy highlights need be addressed.

Language: Английский

Citations

0